TUTCRIS - Tampereen teknillinen yliopisto

TUTCRIS

The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy

Tutkimustuotosvertaisarvioitu

Standard

The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. / Wu, Xingchen; Bhattarai, Abhisek; Korkola, Pasi; Pertovaara, Hannu; Eskola, Hannu; Kellokumpu-Lehtinen, Pirkko Liisa.

julkaisussa: Molecular Imaging and Biology, Vuosikerta 19, Nro 5, 2017, s. 787–794.

Tutkimustuotosvertaisarvioitu

Harvard

Wu, X, Bhattarai, A, Korkola, P, Pertovaara, H, Eskola, H & Kellokumpu-Lehtinen, PL 2017, 'The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy', Molecular Imaging and Biology, Vuosikerta. 19, Nro 5, Sivut 787–794. https://doi.org/10.1007/s11307-017-1044-3

APA

Wu, X., Bhattarai, A., Korkola, P., Pertovaara, H., Eskola, H., & Kellokumpu-Lehtinen, P. L. (2017). The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. Molecular Imaging and Biology, 19(5), 787–794. https://doi.org/10.1007/s11307-017-1044-3

Vancouver

Wu X, Bhattarai A, Korkola P, Pertovaara H, Eskola H, Kellokumpu-Lehtinen PL. The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. Molecular Imaging and Biology. 2017;19(5):787–794. https://doi.org/10.1007/s11307-017-1044-3

Author

Wu, Xingchen ; Bhattarai, Abhisek ; Korkola, Pasi ; Pertovaara, Hannu ; Eskola, Hannu ; Kellokumpu-Lehtinen, Pirkko Liisa. / The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. Julkaisussa: Molecular Imaging and Biology. 2017 ; Vuosikerta 19, Nro 5. Sivut 787–794.

Bibtex - Lataa

@article{3302046d6b8048ba8a997743f48426ce,
title = "The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy",
abstract = "Purpose: The aim of this study was to explore the association between liver, mediastinum and tumor 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) uptake during chemotherapy in diffuse large B cell lymphoma (DLBCL). Procedures: Nineteen patients with proven DLBCL underwent positron emission tomography (PET)/X-ray computed tomography scan at baseline, 1 week and 2 cycles after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy, and again after chemotherapy completion. The mean and maximal standardized uptake value (SUVmean and SUVmax) of the liver and mediastinum were measured and correlated with the tumor SUVmax, SUVsum, whole-body metabolic tumor volume (MTVwb), and total lesion glycolysis (TLG). Results: At baseline, both the liver and mediastinum SUVmean and SUVmax correlated inversely with the tumor MTVwb or TLG (p <0.01 or 0.001). The liver SUVmean and SUVmax increased significantly after 1 week of R-CHOP therapy and remained at the high level until chemotherapy completion. The mediastinum SUVmean and SUVmax remained stable during chemotherapy. The tumor SUVmax, SUVsum, MTVwb, and TLG decreased significantly after 1 week of R-CHOP therapy. The change of the liver SUVmean correlated inversely with the change of tumor MTVwb and TLG after 1 week of chemotherapy (p <0.05, respectively). The intersubject variability of liver and mediastinum [18F]FDG uptake ranged from 11 to 26 {\%}. Conclusions: The liver [18F]FDG uptake increased significantly after R-CHOP therapy. One of the possible reasons is the distribution of a greater fraction of the tracer to healthy tissues rather than tumor after effective chemotherapy. The variability of the liver [18F]FDG uptake during chemotherapy might affect the visual analysis of the interim PET scan and this needs to be confirmed in future studies with a large patient cohort. In addition, the intersubject variability of the liver and mediastinum [18F]FDG uptake should be considered.",
author = "Xingchen Wu and Abhisek Bhattarai and Pasi Korkola and Hannu Pertovaara and Hannu Eskola and Kellokumpu-Lehtinen, {Pirkko Liisa}",
year = "2017",
doi = "10.1007/s11307-017-1044-3",
language = "English",
volume = "19",
pages = "787–794",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer Verlag",
number = "5",

}

RIS (suitable for import to EndNote) - Lataa

TY - JOUR

T1 - The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy

AU - Wu, Xingchen

AU - Bhattarai, Abhisek

AU - Korkola, Pasi

AU - Pertovaara, Hannu

AU - Eskola, Hannu

AU - Kellokumpu-Lehtinen, Pirkko Liisa

PY - 2017

Y1 - 2017

N2 - Purpose: The aim of this study was to explore the association between liver, mediastinum and tumor 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) uptake during chemotherapy in diffuse large B cell lymphoma (DLBCL). Procedures: Nineteen patients with proven DLBCL underwent positron emission tomography (PET)/X-ray computed tomography scan at baseline, 1 week and 2 cycles after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy, and again after chemotherapy completion. The mean and maximal standardized uptake value (SUVmean and SUVmax) of the liver and mediastinum were measured and correlated with the tumor SUVmax, SUVsum, whole-body metabolic tumor volume (MTVwb), and total lesion glycolysis (TLG). Results: At baseline, both the liver and mediastinum SUVmean and SUVmax correlated inversely with the tumor MTVwb or TLG (p <0.01 or 0.001). The liver SUVmean and SUVmax increased significantly after 1 week of R-CHOP therapy and remained at the high level until chemotherapy completion. The mediastinum SUVmean and SUVmax remained stable during chemotherapy. The tumor SUVmax, SUVsum, MTVwb, and TLG decreased significantly after 1 week of R-CHOP therapy. The change of the liver SUVmean correlated inversely with the change of tumor MTVwb and TLG after 1 week of chemotherapy (p <0.05, respectively). The intersubject variability of liver and mediastinum [18F]FDG uptake ranged from 11 to 26 %. Conclusions: The liver [18F]FDG uptake increased significantly after R-CHOP therapy. One of the possible reasons is the distribution of a greater fraction of the tracer to healthy tissues rather than tumor after effective chemotherapy. The variability of the liver [18F]FDG uptake during chemotherapy might affect the visual analysis of the interim PET scan and this needs to be confirmed in future studies with a large patient cohort. In addition, the intersubject variability of the liver and mediastinum [18F]FDG uptake should be considered.

AB - Purpose: The aim of this study was to explore the association between liver, mediastinum and tumor 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) uptake during chemotherapy in diffuse large B cell lymphoma (DLBCL). Procedures: Nineteen patients with proven DLBCL underwent positron emission tomography (PET)/X-ray computed tomography scan at baseline, 1 week and 2 cycles after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy, and again after chemotherapy completion. The mean and maximal standardized uptake value (SUVmean and SUVmax) of the liver and mediastinum were measured and correlated with the tumor SUVmax, SUVsum, whole-body metabolic tumor volume (MTVwb), and total lesion glycolysis (TLG). Results: At baseline, both the liver and mediastinum SUVmean and SUVmax correlated inversely with the tumor MTVwb or TLG (p <0.01 or 0.001). The liver SUVmean and SUVmax increased significantly after 1 week of R-CHOP therapy and remained at the high level until chemotherapy completion. The mediastinum SUVmean and SUVmax remained stable during chemotherapy. The tumor SUVmax, SUVsum, MTVwb, and TLG decreased significantly after 1 week of R-CHOP therapy. The change of the liver SUVmean correlated inversely with the change of tumor MTVwb and TLG after 1 week of chemotherapy (p <0.05, respectively). The intersubject variability of liver and mediastinum [18F]FDG uptake ranged from 11 to 26 %. Conclusions: The liver [18F]FDG uptake increased significantly after R-CHOP therapy. One of the possible reasons is the distribution of a greater fraction of the tracer to healthy tissues rather than tumor after effective chemotherapy. The variability of the liver [18F]FDG uptake during chemotherapy might affect the visual analysis of the interim PET scan and this needs to be confirmed in future studies with a large patient cohort. In addition, the intersubject variability of the liver and mediastinum [18F]FDG uptake should be considered.

U2 - 10.1007/s11307-017-1044-3

DO - 10.1007/s11307-017-1044-3

M3 - Article

VL - 19

SP - 787

EP - 794

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 5

ER -